Xortx announces pre-phase 3 meeting request with us food and drug administration (fda)

Calgary, alberta, july 07, 2022 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that a type b pre-phase 3 meeting request with the fda was submitted on wednesday, july 6, 2022. the meeting is expected to be held in approximately 70 days from today.
XRTX Ratings Summary
XRTX Quant Ranking